8-K: Select Medical Q1 2026 Results and Merger Update

Select Medical reported Q1 2026 revenue growth of 5.0% to $1.42 billion while progressing toward a $16.50 per share take-private merger.

Summary

• Revenue increased 5.0% year-over-year to $1.42 billion for Q1 2026.
• Net income declined 14.7% to $63.8 million compared to $74.7 million in Q1 2025.
• Adjusted EBITDA fell to $141.6 million from $151.4 million in the prior year period.
• Earnings per share (EPS) decreased to $0.35 from $0.44 in Q1 2025.
• The company declared a cash dividend of $0.0625 per share payable on May 28, 2026.
• A merger agreement is in place to take the company private at $16.50 per share, expected to close in mid-2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while operational results show margin pressure, the primary focus for investors is the pending $16.50 per share merger, which effectively caps the stock's upside.

Positives

• Revenue grew 5.0% to $1.42 billion, driven by strong performance in the rehabilitation hospital segment.
• Rehabilitation hospital segment revenue increased 14.5% and Adjusted EBITDA rose 15.1%.
• The Hart-Scott-Rodino antitrust waiting period for the proposed merger expired on April 27, 2026.
• The company maintains a consistent dividend policy with a $0.0625 per share declaration.

Negatives

• Net income attributable to Select Medical dropped 22.4% to $44.0 million.
• Critical illness recovery hospital Adjusted EBITDA margin contracted from 13.6% to 11.5%.
• Outpatient rehabilitation Adjusted EBITDA margin declined from 7.9% to 6.8%.
• Operating income decreased 12.7% to $98.4 million.

Risks

• Potential failure to complete the proposed merger due to regulatory or stockholder approval hurdles.
• Sensitivity to changes in government reimbursement policies and Medicare certification requirements.
• Ongoing inflationary pressures increasing labor costs and potential shortages of qualified healthcare professionals.
• Dependence on third-party payor policies which could limit future revenue growth.
• Risks associated with integration of acquisitions and joint ventures.

Future Outlook

The company maintains its 2026 outlook with revenue expected between $5.6 billion and $5.8 billion, Adjusted EBITDA between $520 million and $540 million, and EPS between $1.22 and $1.32.

Management Comments

• Management is proceeding with the merger agreement to take the company private at $16.50 per share.
• The Board of Directors continues to evaluate dividend payments based on financial condition and cash needs.

Industry Context

StockSavvy.ai notes that Select Medical is navigating a challenging reimbursement environment while simultaneously transitioning toward a private ownership structure, a trend seen in mid-to-large cap healthcare providers seeking to avoid public market volatility.

Comparison to Industry Standards

• Rehabilitation segment growth of 14.5% outperforms general industry benchmarks for outpatient services.
• Margin compression in critical illness recovery hospitals reflects broader industry-wide labor cost inflation affecting post-acute care providers.

Corporate Governance

Legal Proceedings

• The merger is subject to customary litigation risks and regulatory approvals.

Related Party Transactions

• The merger consortium is led by Robert A. Ortenzio (Executive Chairman) and Martin F. Jackson (Senior EVP).

Stakeholder Impact

• Shareholders are expected to receive $16.50 per share upon merger completion.
• Employees face potential changes in management structure post-merger.

Next Steps

• Host conference call on May 1, 2026.
• Pay cash dividend on May 28, 2026.
• Seek stockholder and remaining regulatory approvals for the merger.
• Target merger completion in mid-2026.

Key Dates

Recommendation

The stock is effectively tethered to the $16.50 merger price; investors should hold until the transaction closes or regulatory hurdles emerge.

Keywords

Select Medical, SEM, Merger, Healthcare, Rehabilitation, Earnings, Dividend